MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance

The colorectal epithelium is rapidly renewing, with remarkable capacity to regenerate following injury. In colorectal cancer (CRC), this regenerative capacity can be co-opted to drive epithelial plasticity. Although oncogenic MAPK signalling in CRC is common, with frequent mutations of both KRAS (40-50%) and BRAF (10%)<sup>1</sup>, inhibition of this pathway typically drives resistance clinically. Here, given the development of KRAS inhibitors and licensing of BRAF inhibitor combinations<sup>2-4</sup>, we have interrogated key mechanisms of resistance to these agents in advanced preclinical CRC models. We show that oncogenic MAPK signalling induces epithelial-state changes in vivo, driving adoption of a regenerative/revival stem-like population, whereas inhibition leads to rapid transcriptional remodelling of both Kras-mutant and Braf-mutant tumours, favouring a WNT-associated, canonical stem phenotype. This drives acute therapeutic resistance in Kras-driven and delayed resistance in Braf-driven models. Where plasticity is restrained, such as in early metastatic disease, or through targeting ligand-dependent WNT pathway Rnf43 mutations, marked therapeutic responses are observed. This explains the super response to BRAF + EGFR-targeted therapies previously observed in a BRAF-RNF43 co-mutant patient population, highlighting the criticality of cellular plasticity in therapeutic response. Together, our data provide clear insight into the mechanisms underpinning resistance to MAPK-targeted therapies in CRC. Moreover, strategies that aim to corral stem cell fate, restrict epithelial plasticity or intervene when tumours lack heterogeneity may improve therapeutic efficacy of these agents.

Authors

Institutions

Publication Details

Journal
Nature
Published
2025-11-24
DOI
https://doi.org/10.1038/s41586-025-09916-w
Citations
5
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
5.23
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance

Alexander Raven, Mark White, Lucas Zeiger, Sabine Tejpar et al.
5 citations
Nature
Cancer Cells and Metastasis
5.23
article

MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance

Alexander Raven, Mark White, Lucas Zeiger, Sabine Tejpar, Catriona A. Ford, Yourae Hong, Catherine Ficken, Nikola Vlahov, Susanti Susanti, René Jackstadt, Simon T. Barry, Kathryn Gilroy, Colin Nixon, Richard H. Wilson, Valeria Pavet, Rachel A. Ridgway, John Le Quesne, Nadia Nasreddin, Tamsin R.M. Lannagan, Andrew D. Campbell, Owen J. Sansom, Arafath K. Najumudeen, Andrew S. Papanastasiou, Philip D. Dunne, Janet Graham, Crispin Miller, Megan L. Mills, Hannah Tovell, Sarah J. Ross, Rachel Pennie, Simon J. Leedham, Raheleh Amirkhah, Shania M. Corry, Leah Officer-Jones, Lucile Grzesiak, Ayse Seda Yazgili, Laura M. Millett, Vivienne Morrison, Robert U. Simpson, Eklavya Chauhan, A. Ligęza
article en
5 citations

Abstract

The colorectal epithelium is rapidly renewing, with remarkable capacity to regenerate following injury. In colorectal cancer (CRC), this regenerative capacity can be co-opted to drive epithelial plasticity. Although oncogenic MAPK signalling in CRC is common, with frequent mutations of both KRAS (40-50%) and BRAF (10%)<sup>1</sup>, inhibition of this pathway typically drives resistance clinically. Here, given the development of KRAS inhibitors and licensing of BRAF inhibitor combinations<sup>2-4</sup>, we have interrogated key mechanisms of resistance to these agents in advanced preclinical CRC models. We show that oncogenic MAPK signalling induces epithelial-state changes in vivo, driving adoption of a regenerative/revival stem-like population, whereas inhibition leads to rapid transcriptional remodelling of both Kras-mutant and Braf-mutant tumours, favouring a WNT-associated, canonical stem phenotype. This drives acute therapeutic resistance in Kras-driven and delayed resistance in Braf-driven models. Where plasticity is restrained, such as in early metastatic disease, or through targeting ligand-dependent WNT pathway Rnf43 mutations, marked therapeutic responses are observed. This explains the super response to BRAF + EGFR-targeted therapies previously observed in a BRAF-RNF43 co-mutant patient population, highlighting the criticality of cellular plasticity in therapeutic response. Together, our data provide clear insight into the mechanisms underpinning resistance to MAPK-targeted therapies in CRC. Moreover, strategies that aim to corral stem cell fate, restrict epithelial plasticity or intervene when tumours lack heterogeneity may improve therapeutic efficacy of these agents.

NatureVol. 650(8102)
Queen's University Belfast (GB), Centre for Human Genetics (GB), German Cancer Research Center (DE), Heidelberg University (DE), Beatson West of Scotland Cancer Centre (GB), Cancer Research UK (GB), John Radcliffe Hospital (GB), University of Oxford (GB), Oxford BioMedica (United Kingdom) (GB), Heidelberg Institute for Stem Cell Technology and Experimental Medicine (DE), AstraZeneca (Germany) (DE), University of Glasgow (GB), KU Leuven (BE)
Openalex Percentile: Top 4%
Cancer Cells and Metastasis
5.23
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.